Stock Ratings / Health Care / CTSO / earnings

CNSY (36) GUTS (52) SINT (37) PAVM (31) ⌘ Pro Terminal →

Cytosorbents Corporation (CTSO) Next Earnings Date & Expected ±12.5% Move

$4.40 -16.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cytosorbents Corporation (CTSO) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $13.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-16.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTSO)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.55 Expected Swing

MODEL EARNINGS SETUP GAUGE

CTSO Quantitative Pre-Earnings Setup: 21/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (21/100)Model Risk Weight (79/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$37.1M	-$8.2M	-$12.5M	71.5%
FY 2024	2024-12-31	$35.6M	-$20.7M	-$14.7M	69.9%
FY 2023	2023-12-31	$0	-$29.2M	-$21.7M	71.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTSO)

✓Walkthrough of CTSO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTSO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -63.93%▼ DESCENDING CHANNEL

2026-10-30O $4.39H $4.70L $4.35C $4.40VOL 24.1K

RES: $6.53SUP: $1.99SMA50: $5.30SMA200: $9.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTSO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTSO Butterfly Map → + Track CTSO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTSO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTSO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTSO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTSO)

Health Care Rank #1012 of 1016 ⚔️ CNSY vs CTSO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTSO vs. CNSY, GUTS, SINT, PAVM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cytosorbents Corporation (CTSO) ranks #1012 by composite RQD confidence (21/100, grade E) and #864 by equity capitalization ($13.9M). Within this direct 5-issuer industry benchmark cohort, CTSO leads on earnings valuation at N/A trailing P/E, while CTSO leads on capital efficiency and profitability with -35.0% ROIC and 71.5% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with CTSO at 21/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTSO ACTIVE Cytosorbents Corporation	E	21/100	—	71.5%	-35.0%	-16.03%	$13.9M	Benchmark Subject
CNSY Cerenome Inc.	D-	36/100	—	—	-35.0%	0.00%	$13.2M	/cnsy-vs-ctso →
GUTS Fractyl Health Inc.	D+	52/100	—	—	-35.0%	+11.40%	$13.2M	/guts-vs-ctso →
SINT SiNtx Technologies Inc.	D-	37/100	—	45.3%	-35.0%	-1.15%	$13.0M	/sint-vs-ctso →
PAVM PAVmed Inc.	E	31/100	—	-30.0%	-35.0%	-5.29%	$15.8M	/pavm-vs-ctso →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001175151

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cytosorbents Corporation (CTSO) reported GAAP revenue of $37.1M (+4.1% vs. FY2024 revenue of $35.6M ) , GAAP net income of -$8.2M, operating cash flow of -$12.4M, and free cash flow of -$12.5M (+14.8% YoY). On the balance sheet, CTSO closed FY2025 with $44.2M in total assets against $16.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$37.1M	-$8.2M	-$12.4M	-$12.5M	$44.2M	$16.7M
FY2024 (FY)	2024-12-31	$35.6M	-$20.7M	-$14.4M	-$14.7M	$47.4M	$14.0M
FY2023 (FY)	2023-12-31	$0	-$29.2M	-$21.7M	-$21.7M	—	—

3. CTSO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTSO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cytosorbents Corporation (NASDAQ: CTSO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $4.40 (-16.03% 1D, market cap $13.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CTSO ranks #1012 in composite RQD confidence.

How does CTSO compare to CNSY and GUTS in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), CTSO carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of 71.5%, and ROIC of -35.0%. By comparison, CNSY (Cerenome Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and GUTS (Fractyl Health Inc.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M). Among the 5-stock peer group, CTSO leads on earnings multiple (N/A) while CTSO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTSO?

Per CTSO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001175151), Cytosorbents Corporation generated $37.1M in revenue (+4.1% YoY), -$8.2M in net income, and -$12.5M in free cash flow against $44.2M in total assets and $16.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTSO trading relative to its 50-day, 200-day, and 52-week technical levels?

CTSO last traded at $4.40 (-16.03% on volume of 48,307 shares), positioning the stock -16.98% below its 50-day simple moving average ($5.30) and -53.64% below its 200-day simple moving average ($9.49). Across its 52-week range of $2.84 to $17.00, CTSO sits at the 11.0% percentile with a 14-day RSI of 47.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.85 to $4.95).